Q-omics provides the consensus-scored FAM180A profile across patient tissues and cancer cell-line models. FAM180A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM180A is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, FAM180A RNA expression shows 17,991 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, KICH, and LUAD as cancer lineages where FAM180A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM180A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM180A survival associations across molecular data types. FAM180A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM180A RNA expression–survival associations across cancer types. High FAM180A expression shows unfavorable associations in BLCA, STAD, OV, THCA and UCS, but favorable associations in HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM180A RNA expression.
This table summarizes FAM180A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FAM180A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM180A shows lower tumor expression in KICH, KIRC, THCA, KIRP, LIHC and BLCA. The KICH box plot shows higher FAM180A RNA expression in normal versus tumor tissue (log2 FC = −2.817, t-test p < 0.001).
This table shows molecular features associated with FAM180A in patient tissues and cancer cell lines. In patient samples, FAM180A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM180A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
